Opko Health Inc (OPK)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its...

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company...

Form 8-K - Current report